Table 4 Provision of information for type of main product discussed
Information | Â | New medicine | Â | Old medicine with new information/indication | Â | Old medicine with general information | Â |
|---|---|---|---|---|---|---|---|
Type of product | Â | Australia n/9 (%) | Malaysia n/41 (%) | Australia n/18 (%) | Malaysia n/54 (%) | Australia n/31 (%) | Malaysia n/30 (%) |
Indications | Yes | 8 (89) | 39 (96) | 17 (94) | 49 (91) | 27 (87) | 28 (93) |
| Â | No | 1(11) | 1(2) | 1 (6) | 4 (7) | 4 (13) | 2 (7) |
| Â | Unsure | 0 | 1(2) | 0 | 1 (2) | 0 | 0 |
| Â | Â | Â | Â | ^*P = 0.72 | Â | Â | Â |
| Â | Â | Â | Â | &*P = 0.56 | Â | Â | Â |
Dosage | Yes | 7 (78) | 35 (85) | 14 (78) | 45 (83) | 23 (74) | 23 (77) |
| Â | No | 2 (22) | 6 (15) | 4 (22) | 9 (17) | 8 (26) | 7 (23) |
| Â | Â | Â | Â | ^P = 0.95 | Â | Â | Â |
| Â | Â | Â | Â | &P = 0.62 | Â | Â | Â |
Contraindications | Yes | 5 (55) | 24 (59) | 4 (22) | 20 (37) | 10 (32) | 6 (20) |
| Â | No | 3 (33) | 17 (41) | 13 (72) | 32 (59) | 21 (68) | 23 (77) |
| Â | Unsure | 1 (12) | 0 | 1 (6) | 2 (4) | 0 | 1 (3) |
| Â | Â | Â | Â | ^*P = 0.15 | Â | Â | Â |
| Â | Â | Â | Â | &*P = 0.01 | Â | Â | Â |
Precautions | Yes | 4 (45) | 17 (41) | 5 (28) | 14 (26) | 12 (39) | 7 (23) |
| Â | No | 4 (45) | 23 (57) | 12 (66) | 38 (70) | 18 (58) | 21 (70) |
| Â | Unsure | 1 (12) | 1 (2) | 1 (6) | 2 (4) | 1 (3) | 2 (7) |
| Â | Â | Â | Â | ^*P = 0.59 | Â | Â | Â |
| Â | Â | Â | Â | &*P = 0.19 | Â | Â | Â |
Drug interactions | Yes | 5 (55) | 16 (39) | 3 (16) | 11 (20) | 11 (35) | 4 (13) |
| Â | No | 4 (45) | 23 (56) | 14 (78) | 41 (76) | 20 (65) | 25 (84) |
| Â | Unsure | 0 | 2 (5) | 1 (6) | 2 (4) | 0 | 1 (3) |
| Â | Â | Â | Â | ^*P = 0.14 | Â | Â | Â |
| Â | Â | Â | Â | &*P = 0.02 | Â | Â | Â |
Adverse effects | Yes | 6 (67) | 23 (57) | 7 (39) | 16 (30) | 11 (35) | 6 (20) |
| Â | No | 3 (33) | 17 (41) | 11 (61) | 34 (63) | 19 (62) | 22 (73) |
| Â | Unsure | 0 | 1 (2) | 0 | 4 (7) | 1 (3) | 2 (7) |
| Â | Â | Â | Â | ^*P = 0.26 | Â | Â | Â |
| Â | Â | Â | Â | &*P = 0.01 | Â | Â | Â |